Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
55
resultados
Última actualización
27/06/2026 [06:45:00]
Resumen de: EP4763279A2
This disclosure provides methods of treating a myelodysplastic syndrome (MDS) in a subject that is naive to treatment with an agent selected from a hypomethylating agent (HMA) and lenalidomide, or both. The method includes administering to the subject an effective amount of a telomerase inhibitor, such as e.g. imetelstat or imetelstat sodium. In some cases, the subject treated is classified as low or intermediate-1 IPSS risk MDS and/or have MDS relapsed/refractory to Erythropoiesis-Stimulating Agent (ESA).
Resumen de: EP4763863A1
Provided are an anti-BCMA single-domain antibody, and a preparation method therefor and the use thereof. Specifically, provided is a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity, can thoroughly specifically target BCMA-positive cells, and can be applied to the detection of BCMA expression in bone marrow cells of MM patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating BCMA-target-related diseases (such as multiple myeloma, B-cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma and Hodgkin's lymphoma); or a BCMA protein detection kit, etc. The single-domain antibody has a stable structure, a small molecular size, is easily recombinantly expressed and has a low production cost, can be used alone or as a drug delivery system to carry relevant drugs, and has very wide prospects and important significance in fields such as drug application and clinical diagnosis.
Resumen de: WO2026128374A1
Engineered extracellular vesicle having a first fusion protein comprising an anti-CD3 antibody moiety, an anti-CLL-1 antibody moiety, and a first transmembrane domain, a second 5 fusion protein comprising a PD-1 protein, a second transmembrane domain, and a CD70 protein, such that both the first fusion protein and the second fusion protein are displayed on a surface of the engineered extracellular vesicle, and methods of using the same.
Resumen de: AU2024370696A1
Methods are provided for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, PTPN-11 and/or CBL mutation; (b) identifying a dominant CBL mutation of CBL variant allele frequency of from <5% to >10%; and (c) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody.
Resumen de: US20260166038A1
A method of enhancing the efficacy of a targeted protein degrader and its derivative therapeutics is provided. The mTOR inhibitor can significantly enhance the degradation of substrates by targeted protein degraders such as molecular glue degraders and PROTACs, thereby achieving therapeutic purposes. Moreover, the combination therapy is particularly suitable for myeloma patients who have developed resistance to immunomodulatory drugs (IMiDs), a kind of molecular glue degrader, of which the continuous use resulting in reduced treatment efficacy and myeloma relapse. Also provided is a pharmaceutical composition, which comprises a targeted protein degrader and its derivative therapeutics, and a mTOR inhibitor. By promoting the degradation of substrates by targeted protein degrader and its derivative therapeutics, the effectiveness of such drugs in treating disease can be increased.
Resumen de: AU2024370574A1
Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof comprising administering to the subject a BCMAxCD3 bispecific antibody on a monthly dosing schedule.
Resumen de: US20260167647A1
This disclosure provides chemical entities (e.g., a compound, or a pharmaceutically acceptable salt thereof, or an atropisomer thereof; or a pharmaceutically acceptable salt of an atropisomer) that modulate (e.g., inhibit) the interaction between menin and mixed-lineage leukaemia (“MLL”) proteins (e.g., MLL fusion proteins). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a condition, disease or disorder in which aberrant (e.g., increased, e.g., excessive) menin-MLL interaction contribute to the pathology, symptoms and/or progression of the condition, disease or disorder (e.g., cancer, diabetes). This disclosure also provides compositions containing the chemical entities as well as methods of making and using the same . . . .
Resumen de: US20260166122A1
Use of a micropeptide MIAC, which belongs to the technical field of biomedicine. The present disclosure specifically relates to use of the micropeptide MIAC in preparation of a reagent or a medicament for detecting, preventing or treating tumors. The tumors comprise one or more of solid tumors and hematologic malignancies, such as pancreatic cancer, hepatocellular carcinoma, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancies, myeloma, cholangiocarcinoma and prostate cancer. The micropeptide MIAC has the effects of inhibiting growth, proliferation and/or migration of various tumor cells, has a wide treatment spectrum, and is suitable for diagnosing, preventing or treating various tumors, specifically malignant tumors.
Resumen de: US20260166082A1
Provided herein are adoptive cell therapy methods involving the administration of genetically engineered cells followed by an immunomodulatory agent maintenance therapy for treating disease and conditions, including certain plasma cell malignancy. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for treating subjects with multiple myeloma (MM), such as high risk multiple myeloma or newly diagnosed multiple myeloma (NDMM). In some embodiments, the methods are for treating subjects who experienced an early relapse, an inadequate response or a suboptimal response after frontline autologous stem cell transplant therapy (ASCT).
Resumen de: WO2025035020A2
Provided herein are methods for treating a disease or condition selected from the group consisting of cancer, autoimmune disease, graft or transplant-related condition, neurodegenerative disease, fibrotic-associated condition, ischemic-related conditions, infection (viral, parasitic or prokaryotic) and diseases associated with bone loss, the method comprising administering to a patient a therapeutically effective amount of carfilzomib or a pharmaceutically acceptable salt thereof at a dose volume of 10 mL/kg or higher. Also provided herein are methods for treating multiple myeloma in a patient, comprising administering to the patient a pharmaceutical composition comprising carfilzomib or a pharmaceutically acceptable salt thereof and an aqueous carrier, wherein the carfilzomib is administered at a dose volume of 2.5 mL/kg or higher and/or at a concentration of less than 2 mg/mL.
Resumen de: US20260159597A1
0000 The present disclosure provides methods for treating multiple myeloma. In certain embodiments, the present methods comprise administering to a subject in need thereof a BCMA inhibitor (e.g., a bispecific antibody or antigen-binding fragment thereof that binds to BCMA and CD3) in combination with a PD1 inhibitor or PD-L1 inhibitor (e.g., an anti-PD1 antibody or an anti-PD-L1 antibody). In certain embodiments, the subject has been previously treated with one or more anti-cancer therapies.
Resumen de: US20260159598A1
0000 The present disclosure provides methods for treating multiple myeloma. In certain embodiments, the present methods comprise administering to a subject in need thereof a BCMA inhibitor (e.g., a bispecific antibody or antigen-binding fragment thereof that binds to BCMA and CD3) in combination with an immunomodulator. In certain embodiments, the immunomodulator is a structural or functional analogue of thalidomide (e.g., lenalidomide or pomalidomide). In certain embodiments, the subject has been previously treated with one or more anti-cancer therapies.
Resumen de: US20260158137A1
0000 The present disclosure provides methods for treating multiple myeloma. In certain embodiments, the present methods comprise administering to a subject in need thereof a BCMA inhibitor (e.g., a bispecific antibody or antigen-binding fragment thereof that binds to BCMA and CD3) in combination with a LAG3 inhibitor (e.g., an anti-LAG3 antibody). In certain embodiments, the subject has been previously treated with one or more anti-cancer therapies.
Resumen de: US20260159608A1
0000 Provided herein are, inter alia, novel antibodies that bind to fms-like tyrosine kinase 3 (FLT3) thereby effectively targeting cells expressing FLT3. The antibodies provided herein may be used, inter alia, for therapeutic cancer applications, including, in some embodiments, treatment of multiple cancer types, which may include acute myeloid leukemia (AML), lymphoblastic leukemia (ALL), lung cancer, breast cancer, pancreatic cancer, ovarian cancer, colorectal cancer, renal cancer, or glioblastoma.
Resumen de: WO2026122725A1
Disclosed herein are methods of treating cancer comprising administering an effective amount of a probiotic bacteria to a human patient with cancer optionally in combination with a VIP antagonist. In certain embodiments, the cancer is a hematological cancer such as leukemia. In certain embodiments, the subject is diagnosed with acute myeloid leukemia. In certain embodiments, the probiotic bacteria increase long chain fatty acids in the lumen of the intestine. In certain embodiments, this disclosure relates to probiotic compositions for uses in treating or preventing cancer as reported herein.
Resumen de: US20260159527A1
0000 Described are the compounds, compositions and methods of treating diseases and disorders that involve aberrant B-cell lymphoma 6 (BCL6) activity.
Resumen de: WO2026119257A1
Disclosed in the present invention is the use of an anti-CD20 antibody-drug conjugate in the preparation of a drug for treating diffuse large B-cell lymphoma transformed from indolent B-cell lymphoma. The drug exhibits a good clinical efficacy in the treatment of diffuse large B-cell lymphoma transformed from indolent B-cell lymphoma, is safe and controllable, and can meet currently unmet clinical requirements.
Resumen de: WO2026120530A1
The present disclosure relates to the field of pharmacy, particularly to a NLRP3 inhibitor, for use in treating myeloid diseases, in particular myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS), for the manufacture of a medicament for treating myeloid diseases, in particular myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS).
Resumen de: US20260158048A1
0000 Disclosed herein are methods for treating, managing, or ameliorating a disease selected from myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), MPN/MDS, clonal cytopenia of undetermined significance (CCUS), chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). The methods comprise administering to a subject in need thereof a therapeutically effective amount of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1H-pyrazol-4-yl)carbamoyl)thiazol-2-yl)-1H-pyrazol-1-yl)ethyl phosphate or a stereoisomer or mixture of stereoisomers, a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
Resumen de: WO2026122941A1
Methods of treating non-Hodgkin lymphoma by administering a multispecific antibody to a patient in need are provided. Methods of making such antibodies, and compositions, including pharmaceutical compositions, comprising such antibodies, are also provided.
Resumen de: US20260159595A1
Antibodies and antigen binding fragments that specifically bind to IL-7Rα are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7Rα using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7Rα, such as acute lymphoblastic leukemia.
Resumen de: US20260158153A1
0000 The disclosure is directed to an antibody and an antibody-drug conjugate (ADC) including a monoclonal antibody, or an antigen-binding fragment thereof, conjugated to a cytotoxin, directed against B-cell maturation antigen (BCMA). The BCMA antibody and its ADCs are useful for treatment of multiple myeloma cells, B-cell mediated or plasma cell mediated disease, and immune disorders as well as for detecting BCMA. Further disclosed are pharmaceutical compositions and medical treatment methods.
Resumen de: US20260159599A1
0000 The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of an anti-CD20/anti-CD3 bispecific antibody.
Resumen de: US20260159887A1
0000 Inflammatory bowel disease (IBD) in humans and dogs and other companion animals is characterized by infiltration of lymphocytes and macrophages into the mucosa and submucosa and clinical signs of gastrointestinal (GI) dysfunction (diarrhea, malabsorption, weight loss). Alteration of the gut environment and development of dysbiosis may allow the overgrowth of pathogenic bacteria and induction of intestinal injury and inflammation in IBD. What is needed are novel methods that allow for rapid diagnosis of IBD (and follow-up monitoring) and treatment of the disease. The present disclosure relates to methods for diagnosing and treating inflammatory bowel disease (IBD) or gastrointestinal lymphoma.
Nº publicación: US20260159892A1 11/06/2026
Solicitante:
ANICOM HOLDINGS INC [JP]
NATIONAL UNIV CORPORATION HOKKAIDO UNIV [JP]
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
ANICOM HOLDINGS, INC.
Resumen de: US20260159892A1
The present invention is a post-chemotherapy prognosis prediction method for a canine with lymphoma, including: a measurement step of measuring a methylation rate of one or more CpG sites selected from the group consisting of Chr4: 29559893 and Chr1: 14232692, in DNA recovered from a biological sample collected from a canine as a prediction target; and a prediction step of predicting a post-chemotherapy prognosis for a canine with lymphoma, based on the methylation rate measured in the measurement step and a preset reference value, in which the reference value is a value for differentiating between a canine having a favorable post-chemotherapy prognosis and a canine having a poor post-chemotherapy prognosis, which is set for each methylation rate of each CpG site.
BOPI
Sede Electrónica
